Weekly doxetacel + biweekly Bevacizumab seems to be an effective and well-tolerated treatment option for patients with metastatic castrate resistant prostate cancer previously exposed to Doxetacel based chemotherapy

Francini, F., Pascucci, A., Francini, E., Bargagli, G., Conca, R., Licchetta, A., et al. (2011). Bevacizumab and weekly Doxetacel in patients with metastatic castrate-resistant prostate cancer previously exposed to Docetaxel. PROSTATE CANCER, 2011, 1-7 [10.1155/2011/258689].

Bevacizumab and weekly Doxetacel in patients with metastatic castrate-resistant prostate cancer previously exposed to Docetaxel

MARZOCCA, GIUSEPPE;PONCHIETTI, ROBERTO;SAVELLI, VINNO;
2011-01-01

Abstract

Weekly doxetacel + biweekly Bevacizumab seems to be an effective and well-tolerated treatment option for patients with metastatic castrate resistant prostate cancer previously exposed to Doxetacel based chemotherapy
Francini, F., Pascucci, A., Francini, E., Bargagli, G., Conca, R., Licchetta, A., et al. (2011). Bevacizumab and weekly Doxetacel in patients with metastatic castrate-resistant prostate cancer previously exposed to Docetaxel. PROSTATE CANCER, 2011, 1-7 [10.1155/2011/258689].
File in questo prodotto:
File Dimensione Formato  
Beva.pdf

non disponibili

Tipologia: Post-print
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 557.52 kB
Formato Adobe PDF
557.52 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/22757
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo